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Exposure of perfused livers to zymosan, arachidonic acid or phenylephrine but not to latex particles, stimu- 
lates hepatic constriction. The effects of arachidonic acid are rapid, reach a maximum after 2-3 min and 
then decline. They are blocked by the cyclooxygenase inhibitor indomethacin but not by the lipoxygenase 
inhibitor nordihydroguaiaretic acid. This suggests a role for prostaglandins in this action. Zymosan progres- 
sively increases hepatic pressure after a lag time of about 1 min. Perfusion of bromophenacyl bromide, indo- 
methacin and nordihydroguaiaretic acid only partially inhibits the zymosan-induced vasoconstriction. None 
of these inhibitors affect the phenylephrine-induced response. Repeated infusion of arachidonic acid leads 
to homologous desensitization of the response whereas the response of the liver to phenylephrine is unaf- 
fected. The present data indicate that prostaglandins, produced and released within the liver, affect vasocon- 
striction m this organ. 
Arachidonic acid; Latex particle; Prostaglandin; Vasoconstriction; (Perfused liver) 
1. INTRODUCTION 
It is known that blood flow through the hepatic 
vasculature can be regulated by constriction of the 
portal venules and by sinusoids [l-3]. 
Mechanisms, including those induced by hormones 
such as catecholamines, (Y- and ,&adrenergic 
agonists, serotonin, dopamine, angiotensin and 
vasopressin are known to regulate the hepatic 
blood flow [4]. The role of eicosanoids, which are 
known to be vasoactive in other systems [5], has 
not been investigated in the liver to any great ex- 
tent. In 1939 Von Euler [6] showed that a crude 
prostaglandin preparation increases portal venous 
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pressure in anesthetized cats. A vasodilatory action 
of PGE2 in the hepatic arterial vascular bed of the 
dog has been described [7]. Later Mendlovic and 
co-workers [S] presented some evidence that the 
action of platelet-activating factor (PAF) on 
hepatic blood flow may be mediated by 
eicosanoids. However the origin of the eicosanoids 
remained totally unclear. 
It is well established that the liver consists of 
several cell types with hepatocytes, endothelial 
cells, Kupffer cells and fat storing cells being the 
most predominant. Of these, the sinusoidal cells, 
namely the Kupffer and endothelial cells, are 
known to produce eicosanoids [9-l 11. By contrast, 
the parenchymal cells appear to be involved more 
in the degradation rather than in the synthesis of 
eicosanoids [ 12,131. 
Here, we have examined the vascular effects of 
phagocytosable material like zymosan and latex 
particles in perfused rat liver; these are known to 
interact rather selectively with Kupffer cells [14]. 
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We have also examined the vascular effects of 
arachidonic acid which is converted to eicosanoids 
by both Kupffer and endothelial cells [lo, 1 I]. The 
results described are consistent with the notion that 
prostaglandins are produced and released within 
the liver and that they mediate the vascular effect 
induced by zymosan and arachidonic acid. 
2. EXPERIMENTAL 
2.1. Animals and perfusion 
Wistar-strain albino rats (250-350 g body wt) 
having free access to food were anaesthetized with 
sodium pentobarbitone (50 mg/kg). Livers were 
perfused with Krebs-Henseleit bicarbonate medi- 
um [ 151 containing 1.3 mM CaCl2 and equilibrated 
with OZ/COZ (19: 1) in a flow-through mode as in 
C [16]. After a preperfusion of 15 min, stimuli 
were infused for the appropriate times. Any in- 
hibitors tested were infused 15 min before the ad- 
ministration of the stimuli and thereafter for the 
duration of the experiment. 
2.2. Analytical procedures 
Perfusate oxygen concentrations were con- 
tinuously monitored with a Clark-type oxygen 
electrode as detailed 1161. Portal vein pressure, 
which can be used as an index of intrahepatic 
pressure or vasoconstriction [ 17,181, was deter- 
mined by measuring the changes in the level of the 
perfusion buffer in an open glass capillar tube 
(4 mm 0) connected to the portal inflow. Basal 
portal perfusion pressure was 3.3 + 0.3 mmHg. A 
difference of 10 mmHg was determined to corre- 
spond to a change in flow rate of about 8 ml/min 
at constant pressure. The uptake of zymosan and 
latex particles by the liver was assessed by measur- 
ing the differences in absorbances at 540 nm of the 
inflow and outflow media. Perfusion experiments 
shown are representative xperiments that were 
selected from at least two to five experiments 
which gave essentially identical results. 
2.3. Chemicals and materials 
Zymosan, latex particles (1 ym a), arachidonic 
acid, phenylephrine, indomethacin, nordihydro- 
guaiaretic acid (NDGA), bovine serum albumin 
(fraction V), catalase and superoxide dismutase 
were obtained from Sigma (St. Louis, USA). 
Bromophenacyl bromide (BPB) was purchased 
from Aldrich (Milwaukee, USA). All other 
chemicals were of analytical grade. 
Zymosan suspensions were kept at 95°C for 
30 min to destroy endogenous phospholipase AZ 
activity. Bovine serum albumin was made fatty 
acid-free as described [19]. Arachidonic acid was 
diluted in perfusion buffer containing 10% bovine 
serum albumin and sonicated for 2-3 min. NDGA 
was dissolved in DMSO and infused directly. In- 
domethacin and BPB were dissolved in DMSO and 
slowly added to the perfusion buffer containing 
0. lolo bovine serum albumin. Perfusion with 
DMSO (final concentration 0.03%) or bovine 
serum albumin (0.1 @i’o) alone did not induce any 
change in hepatic pressure. 
3. RESULTS 
3.1. Effect of arachidonic acid, zymosan and latex 
particles on hepatic portal pressure 
The change in hepatic portal pressure induced by 
infusion of arachidonic acid (100 ,uM), zymosan 
(150 pg/min), latex particles (150 pg/min) and 
phenylephrine (2 /IM) into the perfused rat liver is 
shown in fig. 1. Phenylephrine induces a rapid in- 
crease in hepatic pressure which remains elevated 
until the hormone is removed and then declines 
very rapidly to the original level. The pressure 
changes induced by arachidonic acid during the 
Fig. 1. Effects of phenyIephrine, arachidonic acid, 
zymosan and latex particles on hepatic portal pressure. 
Rat livers were perfused for 10 min (arrowed) in the 
presence of 2 ,uM phenylephrine (A), 1OOpM 
arachidonic acid (m), 100 pg/min zymosan (0) and 
lOOpg/min latex particles (0). For further details see 
section 2. 
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first 2-3 min of infusion are very similar to those 
induced by phenylephrine. However a notable dif- 
ference is that the pressure increase induced by 
arachidonic acid decreases after about 3 min even 
though it is still being infused. The pressure then 
remains constant until the arachidonic acid is 
removed and then declines to the original level. 
Zymosan infusion leads to a significant increase in 
hepatic portal pressure after a lag period of 
0.5-l min; thereafter the hepatic pressure in- 
creases constantly up to 10 min of infusion. 
Removal of zymosan leads to a rapid decline in 
hepatic pressure, but in contrast to the removal of 
arachidonic acid and phenylephrine, the hepatic 
pressure does not return to its original level after 
the removal of zymosan. Although about 71 +_ 12 
and 84 + 5% of zymosan and latex particles, 
respectively, are taken up by the liver, no signifi- 
cant pressure change was induced by the latter. 
3.2. Effects of various inhibitors on the 
arachidonic acid- and zymosan-induced 
change in hepatic portal pressure 
To determine whether cyclooxygenase and/or 
lipoxygenase products are involved in the observed 
pressure changes, the livers were perfused with in- 
hibitors of these enzymes prior to the addition of 
the stimuli. Perfusion with the inhibitors alone did 
not result in any significant change in pressure. 
Also the overall shape of the curves as shown in 
fig.1 is not altered by preperfusion with the in- 
hibitors (not shown). Fig.%a shows that the infu- 
sion of BPB, a phospholipase AZ inhibitor [20], 
indomethacin, a cyclooxygenase inhibitor [21], 
NDGA, a lipoxygenase inhibitor [22], or the com- 
bination of these two inhibitors, does not alter the 
pressure changes induced by phenylephrine. The 
changes in hepatic pressure induced by zymosan 
are inhibited to 40-50% by each of these com- 
pounds (fig.2b). In contrast to its effects on 
zymosan, BPB does not inhibit the change in por- 
tal pressure induced by arachidonic acid (fig.2c). 
However after the infusion of indomethacin, or in- 
domethacin plus NDGA, arachidonic acid is no 
longer able to induce any change in hepatic 
pressure. NDGA alone, in contrast to in- 
domethacin alone, produces a stimulatory effect 
on the hepatic pressure change induced by 
arachidonic acid (fig.2c). 
Since it is known that zymosan also induces a 
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Fig.2. Effect of various inhibitors on the increase in 
hepatic portal pressure induced by phenylephrine (a), 
zymosan (b) and arachidonic acid (c). 100 ,uM BPB (B), 
1OpM indomethacin (C), 50 pM NDGA (D) or 
indomethacin and NDGA together (D) were infused 
15 min prior to the infusion of the stimuli and thereafter 
for the duration of the experiment. A represents he 
maximal response induced by the stimuli alone as in 
fig.1. 100% corresponds to a maximal portal pressure 
change of 2.2, 5.1 and 3.0 mmHg/lO g liver induced by 
phenylephrine, zymosan and arachidonic acid, 
respectively. Values are means + SE for 2-4 
experiments. For further details ee section 2. 
release of superoxide in cultured Kupffer cells 
[10,23] we attempted to assess whether this anion 
is involved in the zymosan-induced pressure 
changes. In these experiments, superoxide 
dismutase (50 U/min) and catalase (50 U/min), 
which together convert 02 into 02 and H20, were 
infused 2 min prior to and together with zymosan. 
No significant change in the zymosan-induced 
pressure increase was observed suggesting that 
superoxide anions are not involved in this action of 
zymosan. 
3.3. Effect of repeated administrations of 
phenylephrine, zymosan and arachidonic acid 
on the hepatic portal pressure 
The results in fig.2 suggest hat the mechanisms 
by which phenylephrine, zymosan and arachidonic 
acid induce hepatic vasoconstriction may be dif- 
ferent. To assess this, repeated infusions with 
phenylephrine, arachidonic acid and zymosan were 
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Fig.3. Effect of repeated infusions of phenylephrine, 
arachidonic acid and zymosan on the hepatic portal 
pressure. Phenylephrine, zymosan and arachidonic acid 
were infused initially for 5 min in a, b, c respectively 
(thin arrow); corresponding responses: (A) phenyl- 
ephrine, (e) zymosan, (n) arachidonic acid. At 30 min 
either the same agent, or one of the other two agents (as 
indicated), was infused for a further 5 min (thick 
arrow). For further details ee section 2. 
carried out. For these experiments one of these 
agents was infused for 5 min and subsequently 
either the same or one of the other two agents was 
infused for 5 min after an intervening recovery 
period of 10 min. Fig.3a shows that the initial in- 
fusion with phenylephrine does not alter the 
hepatic portal pressure increase induced by a 
subsequent infusion of phenylephrine, arachidonic 
acid or zymosan. When zymosan is infused first, 
the subsequent phenylephrine-induced change in 
portal pressure is not altered. Moreover the change 
in hepatic pressure induced by a subsequent infu- 
sion with zymosan or arachidonic acid, is inhibited 
by 25-35 and 40-60~~, respectively (fig.3b). An 
initial infusion with arachidonic acid also does not 
lead to a change in the response induced by a 
subsequent infusion of phenylephrine (fig.3c). 
However almost no change in portal pressure can 
be measured after a subsequent infusion of 
arachidonic acid, whereas the response induced by 
a subsequent infusion of zymosan is inhibited by 
,40-60% (fig.3c). 
4. DISCUSSION 
Infusion of zymosan and arachidonic acid into 
rat liver produces an increase in portal vein 
pressure. Since it has been shown that portal vein 
pressure is directly related to hepatic constriction 
[15,16], these results suggest that zymosan and 
arachidonic acid induce constriction of the hepatic 
vasculature. Our results also suggest that the 
mechanism of action of these agents is most 
probably different from that induced by a-adre- 
nergic agonists like phenylephrine. In contrast to 
the zymosan- and arachidonic acid-induced in- 
crease in portal pressure, the increase in pressure 
induced by phenylephrine is not affected by the in- 
hibitors BPB, indomethacin and NDGA (fig.2). 
Repeated infusions of phenylephrine result in the 
pressure changes also being repeated, whereas 
those induced by subsequent infusions with zymo- 
san and arachidonic acid show marked desensitiza- 
tion (fig.3). 
The ability of indomethacin to block almost 
totally the arachidonic acid-induced response sug- 
gests a role for prostaglan~ns in this action. This 
assumption is strongly strengthened by the fact 
that administration of NDGA, a lipoxygenase in- 
hibitor, led to an increase in the arachidonic acid- 
induced pressure change. Arachidonic acid itself 
seems to be vasoinactive since in the presence of in- 
domethacin almost no pressure change could be 
observed during infusion with arachidonic acid 
alone. 
In contrast to the arachidonic acid-induced in- 
crease in portal pressure, that induced by zymosan 
is only partially inhibited by indomethacin, but is 
inhibited to about the same extent by BPB and 
NDGA (fig.2). This suggests that only a part of the 
pressure change induced by zymosan is mediated 
by eicosanoids. The other part may be due to a 
direct effect of zymosan on the perfusion flow 
and/or to a shape change of the Kupffer cells 
which is known to occur after phagocytosis of 
zymosan [ 141. 
These data thus suggest a role of prostaglandins 
in the action of zymosan and arachidonic acid. 
However the origin of the prostaglandins remains 
to be clarified. We suggest that zymosan and 
arachidonic acid act primarily in Kupffer cells and 
endothelial cells. These cells would release pros- 
taglandins after contact with these agents which in 
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turn would react with the hepatic vasculature in- 
ducing the observed pressure changes. The follow- 
ing findings are in agreement with this hypothesis: 
(i) Cultured Kupffer cells and endothelial cells are 
able to release eicosanoids after contact with 
zymosan or with arachidonic acid 19-l 11. (ii) 
Supernatant fractions of z~osan-stimulated 
Kupffer cells are able to contract rabbit femoral 
arteries [ 131. (iii) In contrast to Kupffer cells and 
endothelial cells, hepatocytes eem to be more in- 
volved in the degradation rather than in the syn- 
thesis and release of eicosanoids [12,13]. (iv) 
Zymosan and latex particles (20.8 FM) are selec- 
tively taken up by Kupffer cells [ 141. (v) Latex par- 
ticles which were vasoinactive (fig.1) also do not 
lead to a pronounced release of eicosanoids in 
cultured Kupffer cells (Dieter, P., unpublished), 
although they are taken up by the liver and Kupf- 
fer cells [X0,14]. (vi) Prostaglandins directly in- 
fused into the liver show vasoactivity [6,7]. Further 
investigations are required to establish which 
prostaglandins mediate the vasoconstriction in- 
duced by zymosan and arachidonic acid. 
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